Similar Papers

Paper Title
Journal
Date
Author
Immune-Related Adverse Events and Outcomes in Patients with Advanced Non–Small Cell Lung Cancer: A Predictive Marker of Efficacy?
Jordi Remon ... Benjamin Besse
Journal of Thoracic Oncology | VOL. 14
Jordi Remon, et. al.Jordi Remon ... Benjamin Besse
23 Apr 2019
Second-Line Chemotherapy for Non-small Cell Lung Cancer
John C Ruckdeschel
Chest | VOL. 129
John C RuckdeschelJohn C Ruckdeschel
01 Apr 2006
New Horizons in Chemotherapy: Platforms for Combinations in First-Line Advanced Non-small Cell Lung Cancer
Rogerio C Lilenbaum
Journal of Thoracic Oncology | VOL. 3
Rogerio C LilenbaumRogerio C Lilenbaum
01 Jun 2008
The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in the Therapy of Advanced NSCLC
Fen Wang ... Qing Zhou
Journal of Thoracic Oncology | VOL. 17
Fen Wang, et. al.Fen Wang ... Qing Zhou
17 Mar 2022
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Table of Contents
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
Editorial Board
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
89P Spatial analysis using MultiOmyx hyperplex assay reveals high prevalence of mature tertiary lymphoid structure (TLS) and PDL1 expression in the MSI-high colorectal carcinoma (CRC)
Q Au ... V Chizhevsky
Annals of Oncology | VOL. 35
Q Au, et. al.Q Au ... V Chizhevsky
01 Dec 2024
276MO Epidemiology, treatment (tx) patterns, and clinical outcomes of patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) in Taiwan: A retrospective cohort study
C-T Wu ... L-N Chien
Annals of Oncology | VOL. 35
C-T Wu, et. al.C-T Wu ... L-N Chien
01 Dec 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.